Abacus Global Management 주식 (NASDAQ: ABL)

에 대한 최신 뉴스 Abacus Global Management (NASDAQ:ABL) 주식

Abacus Life

Abacus Global Management Inc is a financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. The Company organizes its business into five reportable segments Active Management, Originations, Asset Management, Portfolio Servicing, and Technology Services. Its operations are confined to the United States.

Abacus Global Management, Inc. - Class A Common Stock

Abacus Global Management Inc

ABALANCE CORP by Abalance Corp.

Abacus FCF Real Assets Leaders ETF

ABLE ENERGY INC by Able Energy, Inc.

Abacus FCF International Leaders ETF

ALTEN BOULOGNE-BILLANCORT by Alten Boulogne-Billancourt

Alten

Abacus Global Management, Inc. - 9.875% Fixed Rate Senior Notes due 2028

Abacus FCF ETF Trust Abacus FCF Small Cap Leaders ETF

AMERICAN BILTRITE INC by American Biltrite, Inc.

American Biltrite Inc

Able View Global Inc. - Class B Ordinary Shares

Able View Global Inc

ABB Ltd

Needham analyst James Ricchiuti maintains Bel Fuse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BELFB#NASDAQ">BELFB</a>) with a Buy and lowers the price target from $100 to $95.

News

Price Target

Analyst Ratings

BELFB

Needham Maintains Buy on Bel Fuse, Lowers Price Target to $95

Acquisition Supports Company's Growth in Innovative Lifestyle Offerings
BETHESDA, Md., April 28, 2025 /PRNewswire/ -- Today, Marriott International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) announced it has reached an agreement to acquire the lifestyle brand <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4414142-1&amp;h=2489686303&amp;u=https%3A%2F%2Fwww.citizenm.com%2F&amp;a=citizenM">citizenM</a>, a unique and innovative offering in the select-service segment. The transaction is expected to accelerate Marriott's global expansion of its select-service and lifestyle lodging offerings, as the company continues to focus on expanding its portfolio to provide even more exciting options for guests and Marriott Bonvoy members around the world.
At closing of the transaction, Marriott will pay $355 million to acquire the brand and related intellectual property. Following closing, the citizenM portfolio will become part of Marriott's system, with the hotels owned and leased by the seller subject to new long-term franchise agreements with Marriott. Stabilized fees for the open and under construction pipeline portfolio are anticipated to be approximately $30 million annually. The seller may also receive earn-out payments up to $110 million that are based on the future growth of the brand over a specified, multi-year timeframe. These payments would not begin until the fourth year following closing.
 &nbsp;

Marriott International Agrees To Acquire citizenM And Its Intellectual Property In $355M Deal

Barclays analyst Paul Kearney initiates coverage on Gildan Activewear (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIL#NYSE">GIL</a>) with a Overweight rating and announces Price Target of $51.

Initiation

Barclays Initiates Coverage On Gildan Activewear with Overweight Rating, Announces Price Target of $51

CSTL

Castle Biosciences Surpasses 200,000 DecisionDx-Melanoma Clinical Test Orders

The ongoing dispute in Louisiana over who should bear the cost of new power plants required for&nbsp;Meta Platforms Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) $10 billion data center is heating up.
What Happened: The Louisiana Public Service Commission received new testimony on April 11 from consumer advocates and climate groups. They urged the state regulator to reject a proposal by Meta&#8217;s electricity provider, Entergy Louisiana, to pass on $5 billion in construction costs for the plants to its entire customer base, <a href="https://www.businessinsider.com/meta-data-center-louisiana-5b-ratepayers-2025-4">reported</a> Business Insider on Saturday.
Entergy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>) has put forward a proposal to construct three new natural gas power plants to support Meta&#8217;s data centers. The utility contends that the data center could have a significant impact on the state, potentially creating 300 to 500 jobs with an average salary of $82,000.
However, advocates and climate groups argued that Entergy&#8217;s 1.1 million electric customers should not bear the cost of Meta&#8217;s power usage. Cathy Kunkel, an energy consultant, also cautioned that the utility&#8217;s plan could &#8220;put other ratepayers at risk of having to absorb hundreds of millions, if not billions of dollars, of additional costs&#8221; tied to Meta&#8217;s data center.
Even Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) in Louisiana has raised concerns, seeking a guarantee that Meta&#8217;s increasing power demand will not affect it or other Entergy customers in the state.
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/04/45003759/arks-bitcoin-bear-case-is-300000-by-2030-whats-the-bull-case" target="_blank" rel="noreferrer noopener">ARK&#8217;s Bitcoin &#8216;Bear Case&#8217; Is $300,000 By 2030—What&#8217;s The Bull Case? &#8211; Benzinga</a>
Why It Matters: &nbsp;The controversy surrounding the funding of Meta&#8217;s data center highlights the broader issue of who should bear the cost of tech companies&#8217; increasing power consumption. As these companies continue to expand their data centers, the demand for electricity is likely to rise, potentially leading to higher costs for consumers.&nbsp;
These concerns stem from the fact that Meta&#8217;s power requirements have grown since the company <a href="https://www.benzinga.com/24/12/42337936/meta-unveils-10-billion-ai-data-center-in-louisiana-a-game-changer-for-tech-and-jobs">first revealed </a>its intention to construct an AI data center in Louisiana, which has contributed to higher service costs for Entergy. The precise amount of additional electricity Meta is requesting remains unclear, as the relevant details have been redacted from the filings.
This situation is further complicated by the reports of recent pullout of Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) from data center leases, raising questions about the sustainability of the AI development boom.&nbsp;However, Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Amazon have recently <a href="https://www.benzinga.com/25/04/45001873/amazon-and-nvidia-dismiss-fears-of-ai-data-center-pullback-we-continue-to-see-very-strong-demand">denied reports</a> of slowdown in AI data center construction. 
The momentum rating of META is 75.93% while its growth rating is 75%, according to&nbsp;<a href="https://www.benzinga.com/quote/META" target="_blank" rel="noreferrer noopener">Benzinga&#8217;s Proprietary Edge Rankings</a>. For an in-depth report on more stocks and insights into growth opportunities,&nbsp;<a href="https://www.benzinga.com/screener/top-momentum-stocks" target="_blank" rel="noreferrer noopener">sign</a>&nbsp;<a href="https://www.benzinga.com/screener/top-momentum-stocks" target="_blank" rel="noreferrer noopener">up for Benzinga Edge.</a>
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/25/04/45031932/donald-trump-says-democrats-did-everything-possible-to-destroy-christopher-columbus-vows-to-restore-his-statues-and-reputation" target="_blank" rel="noreferrer noopener">Trump Vows To Bring Back Columbus Day &#8216;From The Ashes,&#8217; Promises To Restore &#8216;Same Rules, Dates And Locations&#8217; &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

Tech

AMZN

MSFT

NVDA

Meta's Louisiana Data Center Sparks Debate Over Who Should Foot The $5 Billion Power Bill: '...Put Other Ratepayers At Risk Of Having To Absorb Hundreds Of Millions,' Says Expert

<ul>
<li>Oral presentation shows ADCT-242 targeting Claudin-6 was well-tolerated and demonstrated potent antitumor activity in ovarian and non-small lung cancer</li>
<li>Poster presentations highlight&nbsp;antitumor activity and safety of novel PSMA-targeted and ASCT2- targeted ADCs</li>
</ul>

ADCT

ADC Therapeutics' Claudin-6 Targeting ADC Shows Strong Single-Agent And Combination Potential In Solid Tumors

Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025
Dose Finding completed with no dose limiting toxicities and preliminary recommended Phase 2 dose (RP2D) identified
5 of 7 best overall response evaluable patients achieved ORR (3 CR, 1 CRh and 1 morphologic leukemia-free state) across all dose cohorts, including 1 CR and 1 CRh in 3 patients in preliminary RP2D cohort
4 of 4 cCR patients were measurable residual disease (MRD) negative as assessed by local standard of care
Early deep responses with SENTI-202 noted across dose levels with all cCRs ongoing as of the data cut and longest durability of 8+ months
Company to host webcast to discuss the new Phase 1 SENTI-202 data today, April 28th at 8:30 AM ET; <a href="https://www.globenewswire.com/Tracker?data=AbxbR4ScrJ0izIo4Ac5VlxUHBOddH6gJTQ2V2yuu38djGt54HInP6iB0FrHdAu9eXGkLs1e8BNnHuvPkTAM4eOUtRU2gn8tsGBJHwLH2M9IHHXKIVb64CkWt6SNdqkU3YpZRIiFL8WAtnhDFJCBK_Q==">Register Here</a>
Announces certain preliminary first quarter 2025 financial results and provides pipeline update
SOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported additional positive preliminary data from a Phase 1 clinical trial of SENTI-202, a potential first-in-class off-the-shelf Logic Gated selective CD33 OR FLT3 NOT EMCN chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy, for the treatment of relapsed/refractory (R/R) hematologic malignancies including acute myeloid leukemia ("AML"). As previously announced, the Company will host a <a href="https://www.globenewswire.com/Tracker?data=qnw9Be6du1Qo9doPNbJ7zdSPx5_1n2-DBTj98Jvxm8KeXiH6VyCDkvCbYRzXMVdCFNOvd1qv77SNVc4uIGAQqbLYB9d08aZoFAghd0w6_xgQbaly1JA0Tig5i-FyAJbfcSHd68iJmdd6ogneh-V6gUyBY3KKv7SStlNlv0XiHZo=">conference call and webcast</a> to discuss the presented data today, April 28, 2025, at 8:30 AM ET (details below).

SNTI

Senti Biosciences Reports Addl Positive Preliminary Data From Phase 1 Clinical Trial Of SENTI-202 For Treatment Of R/R Hematologic Malignancies Including AML

Initial real-world data from nearly 40,000 EYLEA HD patients will provide early insights on effectiveness of EYLEA HD in everyday clinical practice
New indirect comparisons will evaluate EYLEA HD and faricimab on measures of efficacy, dosing frequency and potential economic benefits in patients with wet age-related macular degeneration and diabetic macular edema
&nbsp;Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) today announced the upcoming presentation of 27 abstracts, including eight oral presentations on EYLEA HD&#xAE; (aflibercept) Injection 8 mg in wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR). Among the new results and analyses are initial insights on the real-world use of EYLEA HD in clinical practice, which reinforce the outcomes seen in pivotal trials. These data will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting from May 4 to 8 in Salt Lake City.
"Our data presentations at ARVO reflect the robust and rapidly growing body of evidence that support the use of EYLEA HD becoming the new standard of care for people living with wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy," said Boaz Hirshberg, M.D., Senior Vice President, Clinical Development, Internal Medicine at Regeneron. "This includes new analyses examining the initial real-world experiences of nearly 40,000 patients treated with EYLEA HD showing, in everyday clinical practice, a positive impact through improved vision and longer dosing intervals for patients. Although early, these data reinforce the value EYLEA HD is bringing to patients with serious retinal diseases."
Notable new presentations at ARVO include:
<ul>
<li>Four analyses evaluating initial real-world experiences with EYLEA HD among patients with wAMD or DME, including both those who were previously naive to treatment and those who switched from other anti-vascular endothelial growth factor (VEGF) therapies</li>
<li>A network meta-analysis indirectly comparing the efficacy and number of injections received for EYLEA HD and faricimab in patients with DME or wAMD, based on the longest follow-up data from Phase 3 clinical trials</li>
<li>A modeling analysis of the potential economic benefit of EYLEA HD compared to faricimab for the treatment of patients with wAMD or DME in the U.S. over three years &nbsp;</li>
</ul>
The most common adverse reactions (≥3%) reported in patients treated with EYLEA&nbsp;HD were cataract, conjunctival hemorrhage, intraocular pressure increased, ocular discomfort/eye pain/eye irritation, vision blurred, vitreous floaters,&nbsp;vitreous detachment, corneal epithelium defect and retinal hemorrhage.&nbsp;

Biotech

General

REGN

Regeneron Pharmaceuticals Announces The Upcoming Presentation Of 27 Abstracts, Including Eight Oral Presentations On EYLEA HD Injection 8 MG . Data Will Be Presented at the Association For Research In Vision and Ophthalmology 2025 Annual Meeting May 4 To 8 in Salt Lake City, Utah

These poster presentations feature five of the company's drug candidates: novel tyrosine kinase inhibitor (TKI) olverembatinib (HQP1351), Bcl-2 inhibitor lisaftoclax (APG-2575), FAK/ALK/ROS1 TKI APG-2449, embryonic ectoderm development (EED) inhibitor APG-5918, and IAP antagonist AS03157.

Health Care

AAPG

Ascentage Pharma Presented Results From Five Preclinical Studies During Poster Presentations At The 2025 American Association For Cancer Research Annual Meeting

QuickLogic Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUIK#NASDAQ">QUIK</a>), a leading developer of embedded FPGA (eFPGA) Hard IP and User Tools, ruggedized FPGAs, and Endpoint AI/ML solutions, announced today the delivery of eFPGA Hard IP optimized for Intel 18A technology to a customer that selected QuickLogic's IP for its Test Chip. This milestone marks the first time eFPGA Hard IP has been delivered for a sub-5nm process node and is expected to set new standards for low power consumption, high performance, and optimal silicon area utilization (PPA).
&nbsp;
By leveraging the power of its proprietary Australis&#x2122; IP Generator, QuickLogic established the first <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4413955-1&amp;h=2637068950&amp;u=https%3A%2F%2Fwww.quicklogic.com%2Fefpga-ip%2F&amp;a=eFPGA+Hard+IP">eFPGA Hard IP</a> for Intel 18A in only six months. With foundry-specific Hard IP now completed, customer-specific variants can be delivered even faster. QuickLogic eFPGA Hard IP is supported by two versions of its FPGA User Tools; Aurora, which is comprised of 100% Open-Source components that give designers complete transparency and inspectability, and Aurora Pro, which includes Synopsys&#xAE; Synplify&#xAE; FPGA Logic Synthesis.

INTC

QUIK

QuickLogic Delivers First eFPGA Hard IP for Intel 18A, Setting New Standard for Low Power and High Performance

RDHL

RedHill Biopharma Announces The China National Intellectual Property Administration Formally Allowed A Critical Use Of Composition-Of-Matter Patent For RHB-107, A Potential COVID-19 Treatment

Opera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRA#NASDAQ">OPRA</a>) sees Q2 sales of $134.000 million-$138.000 million vs $134.12 million analyst estimate.

Guidance

OPRA

Opera Sees Q2 Sales $134.000M-$138.000M vs $134.12M Est

<ul>
<li>Approval-in-Principle Received For Up To $900,000 in Government Funding to&nbsp;</li>
<li>Directly Support Globavend's Expansion into the China Market</li>
</ul>

Globavend Gains Government Approval To Expand Into China, Securing Potential $900,000 Non-Dilutive Grant

VYJUVEK approved for the treatment of DEB from birth in Europe
Approval allows for dosing at home or in a healthcare setting, as well as patient or caregiver administration if deemed appropriate by a healthcare professional
PITTSBURGH, April 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) announced today that on April 23, 2025, the European Commission (EC) granted marketing authorization to VYJUVEK&#xAE; (beremagene geperpavec-svdt) for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) who have mutations in the collagen type VII alpha 1 chain (COL7A1) gene, starting from birth. VYJUVEK is designed to address the genetic root cause of DEB by delivering functional copies of the human COL7A1 gene to provide wound healing and sustained functional type VII collagen protein expression with redosing. VYJUVEK is the first corrective medicine approved in Europe for the treatment of DEB. The approval granted by the EC allows for flexible VYJUVEK dosing either at home or in healthcare setting, with the option for patient or caregiver administration if deemed appropriate by a healthcare professional.
This EC decision authorizes the marketing of VYJUVEK in all European Union member states, as well as Iceland, Norway and Liechtenstein. The timing for availability of VYJUVEK in individual countries will depend on multiple factors, including the completion of reimbursement procedures. The Company is planning for its first European launch in Germany in mid-2025.

KRYS

EC Grants Marketing Authorization To Krystal Biotech's VYJUVEK For Treatment Of Wounds In Patients With DEB Who Have Mutations In COL7A1 Gene, Starting From Birth

Opera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRA#NASDAQ">OPRA</a>) raises FY2025 sales outlook from $555.00 million-$570.00 million to $567.00 million-$582.00 million vs $565.46 million estimate.

Opera Raises FY2025 Sales Guidance from $555.00M-$570.00M to $567.00M-$582.00M vs $565.46M Est

Approval of Lynozyfic is based on data showing deep and durable responses in relapsed/refractory multiple myeloma
Lynozyfic will provide a new option with&nbsp;convenient dosing and administration to patients who face cycles of relapse and remission
&nbsp;Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) today announced that the European Commission (EC) has granted conditional marketing approval of Lynozyfic&#x2122; (linvoseltamab) to treat adults with relapsed and refractory (R/R) multiple myeloma (MM). The indication is specific to those who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy. Lynozyfic is a bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on MM cells with CD3-expressing T cells to facilitate T-cell activation and cancer-cell killing.
Lynozyfic is the first BCMAxCD3 therapy approved that can be dosed every four weeks due to a response-adapted regimen if a very good partial response (VGPR) or better is achieved following completion of at least 24 weeks of therapy. The regimen includes monitoring in close proximity of a qualified treatment center for safety during the step-up dosing period (one 24-hour period after the first step-up dose and another 24-hour period after the second step-up dose, if certain safety events occur).
"Despite treatment advances, patients with multiple myeloma inevitably endure relapses, reduced responses to subsequent therapies, and increasingly shorter remissions. For those who develop relapsed and refractory disease after having been exposed to the three major drug classes, it's important to have new therapies with different mechanisms of action like linvoseltamab," said Paula Rodriguez-Otero, M.D., Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona, Navarra, Spain. "In a clinical trial, linvoseltamab demonstrated compelling and impressive efficacy with the potential for complete remission in this patient population, including those with high disease burden. Furthermore, its response-adapted schedule will provide patients a convenient treatment option."
The EC approval is based on results from the pivotal LINKER-MM1 trial (n=117 at the 200 mg dose of Lynozyfic), which demonstrated robust and durable responses in patients with R/R MM. Results showed a 71% objective response rate (ORR), with 50% of patients achieving a complete response (CR) or better, as determined by an independent review committee. The minimal residual disease (MRD) negativity rate in patients achieving a CR or stringent CR was 41% (24 of 58 patients; 95% confidence interval [CI]: 29 to 55). The median duration of response (DOR) was 29 months (95% CI: 19 to not estimable).
The most frequent adverse reactions were musculoskeletal pain (52%), cytokine release syndrome (CRS; 46%), neutropenia (43%), cough (42%), diarrhea&nbsp;(39%), anemia (38%), fatigue (36%), pneumonia (32%), and upper respiratory tract infection (30%).&nbsp;The majority of CRS cases were Grade 1 (35%) or Grade 2 (10%), and there was one case of Grade 3 CRS (0.9%) and no cases of ≥Grade 4 CRS. The median time to first CRS onset was 11 hours (range: -1.1 to 184 hours), with the median time to resolution within 1 day (16 hours; range: 1-96 hours). Grade 3 immune effector cell-associated neurotoxicity syndrome (ICANS; 2.6%) and infections that were Grade 3 or 4 (36%) or fatal (4%) also occurred.
"Lynozyfic is our second approved bispecific antibody – in this case for relapsed/refractory multiple myeloma patients – reinforcing our relentless commitment to transforming cancer care for those who need it most," said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer of Regeneron. "We are excited by the potential of Lynozyfic and its differentiated clinical profile, dosing and administration. Given the strength of the data, we are pursuing a robust clinical development program exploring its use – in earlier lines of therapy as monotherapy and in novel combinations – with the hope of further advancing care for patients."

Regeneron Pharmaceuticals Announces That The European Commission  Has Granted Conditional Marketing Approval Of Lynozyfic To Treat Adults With Relapsed And Refractory Multiple Myeloma

INMD

InMode Lowers FY2025 Adj EPS Guidance from $1.95-$1.99 to $1.64-$1.68 vs $1.93 Est

Kandi Technologies Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNDI#NASDAQ">KNDI</a>) reported quarterly losses of $(0.57) per share. This is a 850 percent decrease over losses of $(0.06) per share from the same period last year. The company reported $37.80 million in sales this quarter. This is a 33.29 percent increase over sales of $28.36 million the same period last year.

Earnings

KNDI

Kandi Technologies Gr Q4 EPS $(0.57) Down From $(0.06) YoY, Sales $37.80M Up From $28.36M YoY

RNTX

Rein Therapeutics To Present New Data On Caveolin Scaffolding Peptides In IPF And Normal Lung Samples At ATS 2025

JP Morgan analyst Michael Mueller initiates coverage on Smartstop Self Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMA#NYSE">SMA</a>) with a Overweight rating and announces Price Target of $36.

JP Morgan Initiates Coverage On Smartstop Self Storage with Overweight Rating, Announces Price Target of $36

Financing

Press Releases

Abacus Life Closes $150 Million Debt Financing Facility to Support Continued Growth

Events

Sidoti Events, LLC's Virtual January Micro-Cap Conference

Abacus Life Completes the Rebranding of FCF Advisors with New ETF and Fee Reductions

Abacus Life Announces Private Exchange of Outstanding Public Warrants

Abacus Life to Announce Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

Abacus Life Announces Rebrand to Abacus Global Management, Unveils Expanded Business Lines

Dynasty Financial Partners Expands Investment Banking Business

Abacus Global Management Reports Fourth Quarter and Full Year 2024 Results

Abacus Global Management Well-Positioned Amid Market Volatility

Abacus Global Management to Announce First Quarter 2025 Financial Results on Thursday, May 8, 2025

ABLLW

ALCO

AMST

APOG

FLXS

HBIO

LCFY

NNBR

RECT

RZLV

SCWO

Abacus Global Management

AIFU

Arthur J. Gallagher

Aon plc Class A Ordinary Shares (Ireland)

Brown & Brown

The Baldwin Insurance Group, Inc. - Class A Common Stock

Baldwin Insurance

Cheche Group Inc. - Class A Ordinary Shares

Cheche Group

Crawford & Company Common Stock

eHealth

GoHealth

Goosehead Insurance, Inc. - Class A Common Stock

Goosehead Insurance

Hagerty

Hippo Holdings

Health In Tech, Inc. - Class A Common Stock

Health In Tech

Huize Holding Limited - American Depositary Shares

Huize Holding

Marsh & McLennan Companies, Inc. Common Stock

Marsh & McLennan Cos

Reliance Global Group, Inc. - Common Stock

Reliance Global Group

Ryan Specialty Holdings, Inc. Class A Common Stock

Ryan Specialty Hldgs

SelectQuote

TIAN RUIXIANG Holdings Ltd - Class A Ordinary Shares

Tian Ruixiang Holdings

TWFG

Waterdrop Inc. American Depositary Shares (each representing the right to receive 10 Class A Ordinary Shares)

Comments

Abacus Global Management

뉴스

에 대한 최신 뉴스 Abacus Global Management (NASDAQ:ABL) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌